Paolo Tini1, Pierpaolo Pastina2, Valerio Nardone2, Lucio Sebaste3, Marzia Toscano2, Clelia Miracco4, Alfonso Cerase5, Luigi Pirtoli6. 1. IstitutoToscanoTumori, Firenze, Italy; Unit of Radiation Oncology, University Hospital of Siena, Siena, Italy. Electronic address: paolo-tini@libero.it. 2. IstitutoToscanoTumori, Firenze, Italy; Radiation Oncology, Department of Medicine, Surgery and Neurological Sciences, University of Siena, Siena, Italy. 3. IstitutoToscanoTumori, Firenze, Italy; Unit of Radiation Oncology, University Hospital of Siena, Siena, Italy. 4. IstitutoToscanoTumori, Firenze, Italy; Pathological Anatomy, Department of Medicine, Surgery and Neurological Sciences, University of Siena, Siena, Italy. 5. IstitutoToscanoTumori, Firenze, Italy; Unit of Neuroradiology, University Hospital of Siena, Siena, Italy. 6. IstitutoToscanoTumori, Firenze, Italy; Unit of Radiation Oncology, University Hospital of Siena, Siena, Italy; Radiation Oncology, Department of Medicine, Surgery and Neurological Sciences, University of Siena, Siena, Italy.
Abstract
BACKGROUND/AIMS: To investigate the combined prognostic value of the EGFR expression level and the MGMT promoter methylation status in Glioblastoma (GB). METHODS: We assessed the EGFR protein expression level by immune-histochemical (IHC) evaluation and the MGMT promoter methylation status by Polymerase Chain Reaction (PCR) in 169 patients affected by GB. We assessed the prognostic significance of combined MGMT methylation status and EGFR expression level in terms of Overall Survival (OS) with univariate and multivariate analysis, and validated this finding using an external data set of GB patient. RESULTS: Clustering survival analysis for the methylation status of MGMT (methMGMT/unmethMGMT) and EGFR expression (High EGFR: H-EGFR; Low EGFR: L-EGFR), identified three different prognostic groups (p=0.001), as follows. Patients with unmethMGMT/H-EGFR had the shortest survival time (median OS: 5 months) and patients co-expressing methMGMT/L-EGFR had the best prognosis (median OS: 35 months), as compared to the other two sub-groups (methMGMT/H-EGFR; unmethMGMT/L-EGFR), which had respectively median OSs of 11 and 12 months. The combined MGMT methylation and EGFR amplification status analysis showed a similar prognostic impact in an independent series, which we used for validation (p=0.001). CONCLUSIONS: The EGFR expression evaluation refines the prognostic value of MGMT methylation status in GBs.
BACKGROUND/AIMS: To investigate the combined prognostic value of the EGFR expression level and the MGMT promoter methylation status in Glioblastoma (GB). METHODS: We assessed the EGFR protein expression level by immune-histochemical (IHC) evaluation and the MGMT promoter methylation status by Polymerase Chain Reaction (PCR) in 169 patients affected by GB. We assessed the prognostic significance of combined MGMT methylation status and EGFR expression level in terms of Overall Survival (OS) with univariate and multivariate analysis, and validated this finding using an external data set of GB patient. RESULTS: Clustering survival analysis for the methylation status of MGMT (methMGMT/unmethMGMT) and EGFR expression (High EGFR: H-EGFR; Low EGFR: L-EGFR), identified three different prognostic groups (p=0.001), as follows. Patients with unmethMGMT/H-EGFR had the shortest survival time (median OS: 5 months) and patients co-expressing methMGMT/L-EGFR had the best prognosis (median OS: 35 months), as compared to the other two sub-groups (methMGMT/H-EGFR; unmethMGMT/L-EGFR), which had respectively median OSs of 11 and 12 months. The combined MGMT methylation and EGFR amplification status analysis showed a similar prognostic impact in an independent series, which we used for validation (p=0.001). CONCLUSIONS: The EGFR expression evaluation refines the prognostic value of MGMT methylation status in GBs.
Authors: Alexandra McAleenan; Claire Kelly; Francesca Spiga; Ashleigh Kernohan; Hung-Yuan Cheng; Sarah Dawson; Lena Schmidt; Tomos Robinson; Sebastian Brandner; Claire L Faulkner; Christopher Wragg; Sarah Jefferies; Amy Howell; Luke Vale; Julian P T Higgins; Kathreena M Kurian Journal: Cochrane Database Syst Rev Date: 2021-03-12
Authors: Samantha Ya Lyn Ang; Lester Lee; Angela An Qi See; Ting Yao Ang; Beng Ti Ang; Nicolas Kon Kam King Journal: BMC Cancer Date: 2020-01-31 Impact factor: 4.430
Authors: Paolo Tini; Valerio Nardone; Pierpaolo Pastina; Giuseppe Battaglia; Clelia Miracco; Lucio Sebaste; Giovanni Rubino; Alfonso Cerase; Luigi Pirtoli Journal: Biomed Res Int Date: 2017-10-12 Impact factor: 3.411